In our series, tumor patients presenting with increased levels of inflammatory markers at the first ERC intervention, defined by a C-reactive protein level higher than 25 mg/l (normal range, 0.5–5 mg/l), had a significantly worse one-year survival than patients without increased inflammation markers (One year survival rate 64.8 % vs. 46.0 %, p = 0.002) (Fig. 2). Here, CRP is linked to neoplasm.